Medtronic plc
95.41USD
-1.1800 (-1.22%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on MDT.
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | 31.2B | 32.4B | 33.5B | 36.4B | 39.0B | 40.4B |
| Q1 | 7.4B | 7.7B | 7.9B | 8.6B | 9.8B | — |
| Q2 | 7.6B | 8.0B | 8.4B | 9.0B | 9.5B | — |
| Q3 | 7.7B | 8.1B | 8.3B | 9.0B | 9.5B | — |
| Q4 | 8.5B* | 8.6B* | 8.9B* | 9.8B* | — | — |
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | 2.82 | 2.76 | 3.61 | 3.73 | 5.98 | 6.41 |
| Q1 | .700 | .590 | .800 | .810 | 1.14 | — |
| Q2 | .320 | .680 | .990 | 1.07 | 1.33 | — |
| Q3 | .920 | .990 | 1.01 | .890 | 1.42 | — |
| Q4 | .885* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| .492* |
| .819* |
| .966* |
| — |
| — |
Debt level and coverage